NCT02900352View on ClinicalTrials.gov

Zonisamide Treatment of Alcohol Use Disorder: an Evaluation of Efficacy and Mechanism of Action

PHASE3CompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

April 22, 2021

Study Completion Date

April 22, 2021

Conditions
Alcohol Use Disorder
Interventions
DRUG

Zonisamide

Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose

DRUG

Placebo

Placebo

Trial Locations (4)

23298

Virginia Commonwealth University, Richmond

06030

UCONN Health, Farmington

06520

Yale University, New Haven

06515

West Haven Veterans Affairs, West Haven

All Listed Sponsors
collaborator

University of Connecticut

OTHER

collaborator

Yale University

OTHER

collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

collaborator

VA Connecticut Healthcare System

FED

lead

Virginia Commonwealth University

OTHER

NCT02900352 - Zonisamide Treatment of Alcohol Use Disorder: an Evaluation of Efficacy and Mechanism of Action | Biotech Hunter | Biotech Hunter